5 terminated, 4 completed, 3 unknown, 2 withdrawn. 14 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 14 | Terminated 5, Completed 4, Unknown 3, Withdrawn 2 |
Follow Aspergillosis: new trials by email Literature Review of Aspergillosis trials Research Report on Aspergillosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Benralizumab in the Treatment of Patients With Severe Asthma With ABPA Fasenra, 30 Mg/mL Subcutaneous Solution - ABPA, Severe Asthma | Phase 4 | Withdrawn | Baylor Research Institute | 2019-12-23 | 2022-02-01 | |
| Posaconazole for the Prevention of Influenza-associated Aspergillosis in Critically Ill Patients SOC +Posaconazole 18 MG/ML (milligram/milliliter), standard of care (SOC) - Aspergillosis; Pulmonary, Invasive (Etiology) | Phase 4 | Completed | Universitaire Ziekenhuizen KU Leuven | 88 | 2017-12-27 | 2025-04-08 |
| Voriconazole for IPA in Chinese Patients With COPD Voriconazole - Invasive Pulmonary Aspergillosis, COPD | Phase 4 | Unknown | Red Cross Hospital, Hangzhou, China | 40 | 2014-10-01 | 2014-09-09 |
| Post Marketing Study to Evaluate the Safety and Efficacy of Micafungin Against Fungal Infections Caused by Candida Spp or Aspergillus Spp Micafungin - Aspergillosis, Candidiasis | Phase 4 | Terminated | Astellas Pharma China, Inc. | 105 | 2014-03-21 | 2024-11-07 |
| Post Marketing Study to Evaluate the Efficacy and Safety of Micafungin Treatment on Invasive Aspergillosis Micafungin - Invasive Aspergillosis | Phase 4 | Terminated | Astellas Pharma China, Inc. | 43 | 2014-03-01 | 2024-11-20 |
| Efficacy and Safety of Caspofungin for Invasive Pulmonary Aspergillosis Underlying Chronic Obstructive Pulmonary Disease caspofungin - Invasive Pulmonary Aspergillosis, Chronic Obstructive Pulmonary Disease | Phase 4 | Unknown | The First Affiliated Hospital of Guangzhou Medical University | 40 | 2012-01-01 | 2014-01-23 |
| Efficacy Of Itraconazole In Chronic Cavitary Pulmonary Aspergillosis Itraconazole, treatment in cavitary pulmonary aspergillosis - Chronic Cavitary Pulmonary Aspergillosis | Phase 4 | Completed | Post Graduate Institute of Medical Education and Research, Chandigarh | 31 | 2010-07-01 | 2012-02-22 |
| An Exploratory Study to Assess Multiple Doses of Omalizumab in Patients With Cystic Fibrosis Complicated by Acute Bronchopulmonary Aspergillosis (ABPA) Omalizumab, Placebo, Itraconazole - Cystic Fibrosis, Allergic Bronchopulmonary Aspergillosis | Phase 4 | Terminated | Novartis Pharmaceuticals | 14 | 2008-11-01 | 2011-09-26 |
| A Study To Assess The Anidulafungin And Voriconazole Concentration In Lung Following Intravenous Administration In Healthy Subjects anidulafungin and voriconazole - Aspergillosis, Candidemia | Phase 4 | Completed | Pfizer | 24 | 2008-09-01 | 2010-02-09 |
| Study to Test the Combination of Voriconazole and Anidulafungin in Patients Who Have, or Are Thought to Have, Invasive Aspergillosis and Who Are Unable to Take a Common Antifungal Therapy (Polyene) voriconazole, anidulafungin - Aspergillosis | Phase 4 | Terminated | Pfizer | 6 | 2008-08-01 | 2010-02-15 |
| Value of Amphotericin B Inhalation for Prophylaxis of Invasive Pulmonary Aspergillosis After Renal Transplantation Amphotericin B - Invasive Pulmonary Aspergillosis | Phase 4 | Unknown | Capital Medical University | 400 | 2008-06-01 | 2009-09-30 |
| A Study to Evaluate the Effectiveness of Voriconazole + Micafungin Versus Voriconazole Alone for Invasive Aspergillosis micafungin, voriconazole - Aspergillosis/Blood, Aspergillosis/Invasive | Phase 4 | Withdrawn | Astellas Pharma Inc | 2007-02-01 | 2015-09-02 | |
| Comparison of 2 Antifungal Treatment (Empirical Versus Pre-Empirical) Strategies in Prolonged Neutropenia Amphotericin B - Malignant Hemopathy, Duration of Neutropenia Following Chemotherapy > 10 Days | Phase 4 | Terminated | Assistance Publique - Hôpitaux de Paris | 300 | 2003-04-01 | 2006-09-21 |
| A Study of the Efficacy and Safety of Voriconazole for the Treatment of Fungal Infections Voriconazole - Candidiasis, Cryptococcosis | Phase 4 | Completed | Pfizer | 7 | 2003-04-01 | 2011-05-16 |
Invasive Pulmonary Aspergillosis (3) · Aspergillosis, Allergic Bronchopulmonary (2) · Candidiasis (2) · Pulmonary Disease, Chronic Obstructive (2) · Asthma (1) · Candidemia (1) · Cryptococcosis (1) · Cystic Fibrosis (1) · Influenza, Human (1) · Mycetoma (1) · Mycoses (1)
Bacterial Infections and Mycoses (14) · Infections (14) · Mycoses (13) · Respiratory Tract Diseases (6) · Lung Diseases (5) · Lung Diseases, Fungal (5) · Pulmonary Aspergillosis (5) · Invasive Fungal Infections (4) · Lung Diseases, Obstructive (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Respiratory Tract Infections (3) · Chronic Disease (2) · Disease Attributes (2)
Voriconazole (5) · Micafungin (3) · Amphotericin B (2) · Anidulafungin (2) · Itraconazole (2) · Caspofungin (1) · Magnesium (1) · Omalizumab (1) · Standard of Care (1) · Therapeutics (1) · benralizumab (1) · posaconazole (1)
Pfizer (3) · Astellas Pharma China, Inc. (2) · Assistance Publique - Hôpitaux de Paris (1) · Astellas Pharma Inc (1) · Baylor Research Institute (1) · Capital Medical University (1) · Novartis Pharmaceuticals (1) · Post Graduate Institute of Medical Education and Research, Chandigarh (1) · Red Cross Hospital, Hangzhou, China (1) · The First Affiliated Hospital of Guangzhou Medical University (1) · Universitaire Ziekenhuizen KU Leuven (1)
China (5) · United States (4) · Belgium (2) · France (2) · Netherlands (2) · Germany (1) · India (1) · Italy (1) · Taiwan (1) · United Kingdom (1)
Chuang Cai, doctor (1) · Feng Ye, MD (1) · Joost Wauters, Phd (1) · Paul Verweij, Phd (1) · Yolanda Mageto, MD (1)
PMID 23496375, PMID 26302738, PMID 33027187, PMID 34050768, PMID 38828958